<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2408210983
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Vanin
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VANCOMYCIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        306
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ASPIRO PHARMA LIMITED" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ASPIRO PHARMA LIMITED
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01XA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Vanin is an antibiotic that belongs to a group of antibiotics called &ldquo;glycopeptides&rdquo;. Vanin works by eliminating certain bacteria that cause infections.</p><p>Vanin powder is made into a solution for infusion or oral solution.</p><p>&nbsp;</p><p>Vanin is used in in all age groups by infusion for the treatment of the following serious infections:</p><p>- Infections of the skin and tissues below the skin.</p><p>&nbsp;</p><p>-&nbsp; Infections of bone and joints.</p><p>&nbsp;</p><p>-&nbsp; An infection of the lungs called &quot;pneumonia&quot;.</p><p>&nbsp;</p><p>-&nbsp; Infection of the inside lining of the heart (endocarditis) and to prevent endocarditis in Patients at risk when undergoing major surgical procedures.</p><p>-&nbsp; Infection in central nervous system</p><p>&nbsp;</p><p>-&nbsp; Infection in the blood linked to the infections listed above.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use Vanin</p><p>-&nbsp;&nbsp;&nbsp; If you are allergic to vancomycin or any of the other ingredients of this medicine (listed in section 6).</p><p>Warnings and precautions</p><p><strong>&nbsp;</strong></p><p>Talk to your doctor or hospital pharmacist or nurse before using Vanin if:</p><p>&nbsp;</p><p>-&nbsp; You suffered a previous allergic reaction to teicoplanin because this could mean you are also allergic to vanin.</p><p>-&nbsp; You have a hearing disorder, especially if you are elderly (you may need hearing tests during treatment).</p><p>-&nbsp; You have kidney disorder (you will need to have your blood and kidneys tested during treatment).</p><p>-&nbsp; You are receiving vancomycin by infusion for the treatment of the diarrhoea associated to Clostridium difficile infection instead of orally.</p><p>Talk to your doctor or hospital pharmacist or nurse during treatment with Vancomycin if:</p><p>&nbsp;</p><p>-&nbsp; You are receiving vancomycin for a long time (you may need to have your blood, hepatic and kidneys tested during treatment).</p><p>-&nbsp; You develop any skin reaction during the treatment.</p><p>&nbsp;</p><p>-&nbsp; You develop severe or prolonged diarrhoea during or after using vancomycin, consult your doctor immediately. This may be a sign of bowel inflammation (pseudomembranous colitis) which can occur following treatment with antibiotics.</p><p>Children</p><p>&nbsp;</p><p>Vancomycin will be used with particular care in premature infants and young infants, because their kidneys are not fully developed and they may accumulare vancomycin in the blood. This age group may need blood tests for controlling vancomycin levels in blood.</p><p>Concomitant administration of vancomycin and anaesthetic agents has been associated with skin redness (erythema) and allergic reactions in children. Similarly, concomitant use with other medicines such as aminoglycoside antibiotics, nonsteroidal anti-inflammatory agents (NSAIDs, e.g., ibuprofen) or amphotericin B (medicine for fungal infection) can increase the risk of kidney damage and therefore more frequent blood and renal test may be necessary.</p><p>Take special care with Vancomycin Hydrochloride Powder for Concentrate for Infusion</p><p>&nbsp;</p><p>&bull;&nbsp; if you have kidney problems</p><p>&nbsp;</p><p>&bull;&nbsp; if you have hearing difficulties</p><p>&nbsp;</p><p>Tell your doctor if either of the above applies to you before this medicine is used.</p><p>&nbsp;</p><p>Special care will also be taken if you are elderly or you are due to have a general anaesthetic. Taking/using other medicines</p><p>Special care is needed if you are taking/using other medicines as some could interact with vancomycin, for example:</p><p>&bull;&nbsp; other antibiotics that can affect your kidneys e.g. streptomycin, neomycin, gentamicin, kanamycin, amikacin, tobramycin, polymyxin B and colistin</p><p>&bull;&nbsp; water tablets e.g. ethacrynic acid and frusemide</p><p>&nbsp;</p><p>&bull;&nbsp; cholestyramine (a medicine used to treat high levels of fat in the blood or diarrhoea in inflammatory diseases of the gut)</p><p>Please tell your doctor if you are taking or have recently taken or might take any other medicines, including medicines obtained without a prescription.</p><p>Pregnancy and breast-feeding</p><p>&nbsp;</p><p>Tell your doctor if you are pregnant, trying to become pregnant or breastfeeding. Your doctor will decide if you should receive this medicine.</p><p>Ask your doctor or pharmacist for advice before taking any medicine. Driving and using machines</p><p>Do not drive or use machines if you experience any side effect (e.g. dizziness) which may lessen your ability to do so.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>You will be given Vancomycin by medical staff while you are in hospital. Your doctor will decide how much of this medicine you should receive each day and how long the treatment will last.</p><p><u>Dosage</u></p><p>The dose given to you will depend on:</p><p>-&nbsp; your age,</p><p>-&nbsp; your weight,</p><p>-&nbsp; the infection you have,</p><p>-&nbsp; how well your kidneys are working,</p><p>-&nbsp; your hearing ability,</p><p>-&nbsp; any other medicines you may be taking.</p><p>Intravenous administration</p><p><strong>Adults and adolescents (from 12 years and older)</strong></p><p>The dosage will be calculated according to your body weight. The usual infusion dose is 15 to 20 mg for each kg of body weight. It is usually given every 8 to 12 hours. In some cases, your</p><p>&nbsp;</p><p>doctor may decide to give an initial dose of up to 30 mg for each kg of body weight. The maximum daily dose should not exceed 2 g.</p><p>Use in children</p><p>Children aged from one month to less than 12 years of age</p><p>The dosage will be calculated according to your body weight. The usual infusion dose is 10 to 15 mg for each kg of body weight. It is usually given every 6 hours.</p><p>Preterm and term newborn infants (from 0 to 27 days)</p><p>The dosage will be calculated according to post-menstrual age (time elapsed between the first day of the last menstrual period and birth (gestational age) plus the time elapsed after birth (post-natal age).</p><p>The elderly, pregnant women and patients with a kidney disorder, including those on dialysis, may need a different dose<strong>.</strong></p><p>Oral administration</p><p><strong>Adults and adolescents (from 12 to 18 years)</strong></p><p>The recommended dose is 125 mg every 6 hours. In some cases, your doctor may decide to give a higher daily dose of up to 500 mg every 6 hours. The maximum daily dose should not exceed 2 g.</p><p>If you suffered other episodes (infection of the mucosa) before you may need different dose and different duration of the therapy.</p><p>Use in children</p><p>Neonates, infants and children less than 12 years old</p><p>The recommended dose is 10 mg for each kg of body weight. It is usually given every 6 hours. The maximum daily dose should not exceed 2 g.</p><p>Method of administration</p><p>Intravenous infusion means that the medicinal product flows from an infusion bottle or bag through a tube to one of your blood vessels and into your body. Your doctor, or nurse, will always give vancomycin into your blood and not in the muscle.</p><p>Vancomycin will be given into your vein for at least 60 minutes.</p><p>If given for treatment of gastric disorders (so called Pseudomembranous colitis), the medicinal product must be administrated as a solution for oral use (you will take the medicine by mouth).</p><p>&nbsp;</p><p>Duration of treatment</p><p>The length of treatment depends on the infection you have and may last a number of weeks. The duration of the therapy may be different depending on the individual response to treatment for every patient.</p><p>During the treatment, you might have blood tests, be asked to provide urine samples and possibly have hearing tests to look for signs of possible side effects.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Vancomycin can cause allergic reactions, although serious allergic reactions (anaphylactic shock) are rare. Tell your doctor immediately if you get any sudden wheeziness, difficulty in breathing, redness on the upper part of the body, rash or itching.</p><p>The absorption of vancomycin from the gastrointestinal tract is negligible. However, if you have an inflammatory disorder of the digestive tract, especially if you also have a kidney disorder, side effects that occur when vancomycin is administered by infusion may appear.</p><p>Common side effects (may affect up to 1 in 10 people):</p><p>-&nbsp; Fall in blood pressure</p><p>-&nbsp;&nbsp; Breathlessness, noisy breathing (a high pitched sound resulting from obstructed air flow in the upper airway)</p><p>-&nbsp; Rash and inflammation of the lining of the mouth, itching, itching rash, hives</p><p>-&nbsp; Kidney problems which may be detected primarily by blood tests</p><p>-&nbsp; Redness of upper body and face, inflammation of a vein Uncommon side effects (may affect up to 1 in 100 people):</p><p>-&nbsp; Temporary or permanent loss of hearing</p><p>Rare side effects (may affect up to 1 in 1,000 people):</p><p>-&nbsp; Decrease in white blood cells, red blood cells and platelets (blood cells responsible for blood clotting)</p><p>Increase in some of the white cells in the blood.</p><p>-&nbsp; Loss of balance, ringing in your ears, dizziness</p><p>-&nbsp; Blood vessel inflammation</p><p>-&nbsp; Nausea (feeling sick)</p><p>-&nbsp; Inflammation of the kidneys and kidney failure</p><p>&nbsp;</p><p>-&nbsp; Pain in the chest and back muscles</p><p>-&nbsp; Fever, chills</p><p>Very rare side effects (may affect up to 1 in 10,000 people):</p><p>-&nbsp;&nbsp; Sudden onset of severe allergic skin reaction with skin flaking blistering or peeling skin. This may be associated with a high fever and joint pains</p><p>-&nbsp; Cardiac arrest</p><p>&nbsp;</p><p>-&nbsp;&nbsp; Inflammation of the bowel which causes abdominal pain and diarrhea, which may contain blood</p><p>Not known (frequency cannot be estimated from the available data):</p><p>&nbsp;</p><p>-&nbsp; Being sick (throwing up), diarrhoea</p><p>&nbsp;</p><p>-&nbsp; Confusion, drowsiness, lack of energy, swelling, fluid retention, decreased urine</p><p>&nbsp;</p><p>Rash with swelling or pain behind the ears, in the neck, groin, under the chin and armpits (swollen lymph nodes), abnormal blood and liver function tests</p><p>-&nbsp; Rash with blisters and fever.</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&bull;&nbsp; Saudi Arabia<em>:</em></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:88.2pt;margin-top:14.85pt;width:382.6pt;height:124.7pt;z-index:-251658240;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight=".48pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:0in;margin-right:67.05pt;
     margin-bottom:0in;margin-left:5.15pt;margin-bottom:.0001pt;line-height:
     150%'>The National Pharmacovigilance and Drug Safety Centre (NPC) o Fax:
     +966-11-205-7662<o:p></o:p></p>
     <p class=MsoBodyText style='margin-left:5.15pt'>o Call NPC at
     +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:6.55pt;margin-right:0in;margin-bottom:
     0in;margin-left:14.15pt;margin-bottom:.0001pt;text-indent:-9.05pt;
     mso-list:l0 level1 lfo1;tab-stops:14.2pt'><![if !supportLists]><span
     style='letter-spacing:-.05pt'><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
     dir=LTR></span>Toll free phone:<span style='letter-spacing:-.1pt'> </span>8002490000<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:6.95pt;margin-right:0in;margin-bottom:
     0in;margin-left:14.15pt;margin-bottom:.0001pt;text-indent:-9.05pt;
     mso-list:l0 level1 lfo1;tab-stops:14.2pt'><![if !supportLists]><span
     style='letter-spacing:-.05pt'><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
     dir=LTR></span>E-mail:<span style='letter-spacing:-.05pt'> </span><a
     href="mailto:npc.drug@sfda.gov.sa"><span style='color:blue;text-decoration:
     none;text-underline:none'>npc.drug@sfda.gov.sa</span></a><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:6.85pt;margin-right:0in;margin-bottom:
     0in;margin-left:14.15pt;margin-bottom:.0001pt;text-indent:-9.05pt;
     mso-list:l0 level1 lfo1;tab-stops:14.2pt'><![if !supportLists]><span
     style='letter-spacing:-.05pt'><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
     dir=LTR></span>Website:<span style='letter-spacing:-.05pt'> </span><a
     href="http://www.sfda.gov.sa/npc"><span style='color:blue;text-decoration:
     none;text-underline:none'>www.sfda.gov.sa/npc</span></a><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>The National Pharmacovigilance and Drug Safety Centre (NPC) o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o&nbsp; Toll free phone: 8002490000</p><p>o&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp; Website: www.sfda.gov.sa/npc</p><p><strong><em>o Other GCC States:</em></strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package in order to protect from moisture.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the vial and on the box. The expiry date</p><p>Reconstitution and Dilution information:</p><p><strong>Primary Diluent </strong>&ndash; Sterile water for Injection</p><p><strong>Secondary Diluent - </strong>5% Dextrose and 0.9% Sodium Chloride Injection</p><p>5% Dextrose and Lactated Ringer&#39;s Injection</p><p><strong>Preparation and Stability:</strong></p><p>At the time of use reconstitute the vials of Vancomycin Hydrochloride for Injection USP with Sterile Water for Injection to a concentration of 50mg /mL of Vancomycin / mL.</p><p>For 500mg Vial : 10mL of Diluent ( Sterile Water For Injection) to be used</p><p>After dilution store below 30&deg;C not more than 24 hours. Or in refrigerator 2 - 8 &deg;C for not more than 36 hours.</p><p>Reconstituted solutions of Vancomycin (500mg/10mL) must be further diluted with at least 100mL of a suitable infusion solution.</p><p>The desired dose, diluted in this manner, should be administered by intermittent IV Infusion over a period of at least 60 minutes.</p><p>Parenteral drug products should be visually inspected for particulate matter and discoloration prior to</p><p>administration, whenever solution and container permit</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Vancomycin Hydrochloride injection contains</strong></p><p>The active substance is Vancomycin Hydrochloride.</p><p><strong>Vancomycin Hydrochloride for Injection USP 500mg/Vial</strong>:</p><p>Each vial contains Vancomycin hydrochloride USP equivalent to 500mg vancomycin.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Vancomycin Hydrochloride for Injection USP 500mg/Vial:

White to tan lyophilized cake or powder present in 20 mL clear USP Type I glass vial with 20mm

grey bromobutyl lyophilization rubber stopper and 20mm flip off seal.

When reconstituted as directed the solution should be clear, light to dark tan colored solution.

How supplied:

Vancomycin Hydrochloride for Injection 500mg/Vial is supplied in glass Vials.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Saudi Amarox Industrial Company</strong></p><p>Aljameah Street, Malaz quarter, Riyadh 11441</p><p>Saudi Arabia</p><p>Tel: +966 11 477 2215</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                11/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي فانكومايسين إلى مجموعة من المضادات الحيوية والتي تسمى &quot;جليكوببتيدات&quot;. حيث يعمل الفانكومايسين عن طريق القضاء على بعض البكتيريا التي تسبب التهابات:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهابات الجلد والأنسجة تحت الجلد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;التهابات العظام والمفاصل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب في الرئتين يسمى &quot;الالتهاب الرئوي&quot;.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إصابة بطانة القلب الداخلية (التهاب الشغاف) ومنع التهاب الشغاف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المرضى المعرضون للمخاطر عند خضوعهم لإجراءات جراحية كبيرة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى في الجهاز العصبي المركزي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الدم المرتبطة بالأمراض المذكورة أعلاه.</p><p dir="RTL">يمكن تناول الفانكومايسين عن طريق الفم في حالة البالغين والأطفال وذلك لعلاج حالات التهاب الغشاء المخاطي في الأمعاء الدقيقة والغليظة مع تلف في الغشاء المخاطي (التهاب القولون الغشائي الكاذب)، الناجم عن بكتيريا المطثية العسيرة (كلوستريديوم ديفيسيل).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تقم باستعمال فنكوسين فيال للحقن:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه مادة فانكومايسين أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6).</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong><strong> </strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي في المستشفى أو الممرضة قبل استخدام فنكوسين فيال للحقن:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عانيت من رد فعل تحسسي سابق تجاه تيكوبلانين لأن هذا قد يعني أنك تعاني أيضًا من حساسية تجاه الفانكومايسين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك اضطراب في السمع، خاصة إذا كنت من كبار السن (قد تحتاج إلى اختبارات سمعية أثناء العلاج).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك اضطراب في الكلى (سوف تحتاج إلى فحص الدم والكلى أثناء العلاج).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتلقى فانكومايسين عن طريق الحقن لعلاج الإسهال المرتبط بالعدوى ببكتيريا المطثية العسيرة (كلوستريديوم ديفيسيل) بدلاً من الفم.</p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي في المستشفى أو الممرضة أثناء العلاج باستخدام فنكوسين فيال للحقن إذا:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتلقى فانكومايسين لفترة طويلة (قد تحتاج إلى فحص الدم والكبد والكلى أثناء العلاج).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أي رد فعل تحسسي جلدي أثناء العلاج.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاب بإسهال شديد أو مزمن أثناء أو بعد استخدام الفانكومايسين، استشر طبيبك على الفور. قد يكون هذا علامة على التهاب الأمعاء (التهاب القولون الغشائي الكاذب) الذي يمكن أن يحدث بعد العلاج بالمضادات الحيوية.</p><p dir="RTL"><strong>الأطفال</strong></p><p dir="RTL">سيتم استخدام الفانكومايسين بعناية خاصة عند الرضع غير مكتملي النمو والرضع الصغار، لأن كليتيهم لم تتطور بالكامل وقد يحدث تراكم لمادة الفانكومايسين في الدم. قد تحتاج هذه الفئة العمرية إلى اختبارات دم للتحكم في مستويات الفانكومايسين في الدم.</p><p dir="RTL">يرتبط تناول الفانكومايسين ومواد التخدير بظهور احمرار بالجلد (حمامي) وردود الفعل التحسسية عند الأطفال. وبالمثل، فإن الاستخدام مع أدوية أخرى مثل المضادات الحيوية (الأمينوغليكوزيد)، والعوامل المضادة للالتهابات غير الستيرويدية (مضادات الالتهاب غير الستيروئيدية، على سبيل المثال، الإيبوبروفين) أو الأمفوتريسين B (دواء للعدوى الفطرية) قد يزيد من خطر تلف الكلى وبالتالي قد يتطلب ضرورة اختبار الدم والكلى بمعدل أكثر.</p><p dir="RTL"><strong>احرص بشكل خاص أثناء تناول فنكوسين فيال للحقن المركّز للتسريب</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل في الكلى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من صعوبات في السمع</p><p dir="RTL">أخبر طبيبك إذا كان أي مما سبق ينطبق عليك قبل استخدام هذا الدواء.</p><p dir="RTL">يجب توخي الحذر أيضًا إذا كنت مسنًا أو كنت على وشك التعرض للتخدير العام.</p><p dir="RTL"><strong>تناول أدوية أخرى مع فنكوسين فيال للحقن </strong></p><p dir="RTL">يجب الحذر بشكل خاص إذا كنت تتناول / تستخدم أدوية أخرى لأن البعض قد يتفاعل مع فانكومايسين، على سبيل المثال:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات حيوية أخرى يمكن أن تؤثر على كليتيك، على سبيل المثال استربتومايسين والنيومايسين والجنتاميسين والكاناميسين والأميكاسين والتوبراميسين والبوليمكسين B والكولستين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أقراص الماء (مدرات البول) على سبيل المثال حمض الإيثاكرينيك وفروسيميد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كوليستيرامين (دواء يستخدم لعلاج ارتفاع مستويات الدهون في الدم أو الإسهال في حالة أمراض التهاب الأمعاء)</p><p dir="RTL">يرجى إخبار طبيبك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها بدون وصفة طبية.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">أخبر طبيبك إذا كنت حاملا، تحاولين أن تصبح حاملا أو مرضعة. سيقرر طبيبك ما إذا كان يجب أن تتلقى هذا الدواء.</p><p dir="RTL">اسأل طبيبك أو الصيدلي للحصول على المشورة قبل تناول أي دواء.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">لا تقم بقيادة السيارة أو استخدام الآلات إذا واجهت أي آثار جانبية (مثل الدوخة) مما قد يقلل من قدرتك على القيام بذلك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتم الحصول على فنكوسين فيال من قبل الطاقم الطبي أثناء وجودك في المستشفى. سيقرر طبيبك مقدار هذا الدواء الذي يجب أن تتلقاه كل يوم والمدة التي سيستغرقها العلاج.</p><p dir="RTL"><strong><u>الجرعة</u></strong></p><p dir="RTL">تعتمد الجرعة التي ستعطى لك على:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عمرك،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وزنك،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة العدوى لديك،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مدى كفاءة كليتيك،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القدرة على السمع،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي أدوية أخرى قد تتناولها.</p><p dir="RTL"><strong>الحقن داخل الوريد</strong></p><p dir="RTL"><strong>البالغون والمراهقون (من 12 سنة وما فوق)</strong></p><p dir="RTL">سيتم حساب الجرعة بناء على وزن جسمك. جرعة التسريب الوريدي المعتادة هي 15 إلى 20 ملغم لكل كيلوغرام من وزن الجسم. وعادة يتم حقنها كل 8 إلى 12 ساعة. في بعض الحالات، قد يقرر طبيبك حقن جرعة أولية تصل إلى 30 ملغم لكل كيلوغرام من وزن الجسم. يجب ألا تتجاوز الجرعة اليومية القصوى 2 غرام.</p><p dir="RTL"><strong>الاستخدام في الأطفال</strong></p><p dir="RTL">الأطفال الذين تتراوح أعمارهم بين شهر واحد إلى أقل من 12 سنة</p><p dir="RTL">سيتم حساب الجرعة بناء على وزن الجسم. جرعة التسريب الوريدي المعتادة هي 10 إلى 15 ملغم لكل كيلوغرام من وزن الجسم. وعادة يتم الحقن كل 6 ساعات.</p><p dir="RTL"><strong>الأطفال الخدّج</strong><strong> والرضع حديثي الولادة (من 0 إلى 27 يومًا)</strong></p><p dir="RTL">سيتم حساب الجرعة وفقًا لسن ما بعد الحيض (الوقت المنقضي بين اليوم الأول لآخر فترة حيض والولادة (عمر الحمل) بالإضافة إلى الوقت المنقضي بعد الولادة (عمر ما بعد الولادة).</p><p dir="RTL">قد يحتاج كبار السن والنساء الحوامل والمرضى الذين يعانون من اضطرابات في الكلى، بما في ذلك أولئك الذين يخضعون لغسيل الكلى، إلى جرعة مختلفة.</p><p dir="RTL"><strong>الاستخدام عن طريق الفم</strong></p><p dir="RTL"><strong>البالغون والمراهقون (من 12 إلى 18 سنة)</strong></p><p dir="RTL">الجرعة الموصى بها هي 125 ملغم كل 6 ساعات. في بعض الحالات، قد يقرر طبيبك إعطاء جرعة يومية أعلى تصل إلى 500 ملغم كل 6 ساعات. يجب ألا تتجاوز الجرعة اليومية القصوى 2 غرام.</p><p dir="RTL">إذا كنت تعاني من نوبات أخرى (عدوى الغشاء المخاطي) فقد تحتاج إلى جرعة مختلفة ومدة مختلفة من العلاج.</p><p dir="RTL"><strong>الاستخدام في الأطفال</strong></p><p dir="RTL">الأطفال حديثي الولادة والرضع والأطفال أقل من 12 سنة</p><p dir="RTL">الجرعة الموصى بها هي 10 ملغم لكل كيلوغرام من وزن الجسم. يعطى عادة كل 6 ساعات. يجب ألا تتجاوز الجرعة اليومية القصوى 2 غرام.</p><p dir="RTL"><strong>طريقة الاستخدام</strong></p><p dir="RTL">التسريب في الوريد يعني أن يتدفق المنتج الطبي من زجاجة أو كيس تسريب عبر أنبوب إلى إحدى الأوعية الدموية وإلى جسمك. طبيبك، أو الممرض، سوف يعطيان دائمًا فنكوسين في دمك وليس في العضلات.</p><p dir="RTL">سيتم إعطاء فنكوسين في الوريد لمدة 60 دقيقة على الأقل.</p><p dir="RTL">إذا كنت تتناول علاج لاضطرابات بالمعدة (ما يسمى التهاب القولون الغشائي الكاذب)، يجب أن يتم استخدام المنتج الطبي كمحلول للاستخدام عن طريق الفم (سوف تتناول الدواء عن طريق الفم).</p><p dir="RTL"><strong>مدة العلاج</strong></p><p dir="RTL">تعتمد مدة العلاج على العدوى التي تعاني منها فقد تستمر عدة أسابيع.</p><p dir="RTL">قد تختلف مدة العلاج حسب الاستجابة الفردية للعلاج لكل مريض.</p><p dir="RTL">خلال فترة العلاج، قد تجرى اختبارات للدم، ويُطلب منك تقديم عينات من البول وربما يكون لديك اختبارات سمعية للبحث عن أعراض الآثار الجانبية المحتملة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، على الرغم من عدم حدوثها للجميع.</p><p dir="RTL">يمكن أن يسبب الفانكومايسين ردود فعل تحسسية، على الرغم من أن تفاعلات الحساسية الخطيرة (صدمة الحساسية) نادرة. أخبر طبيبك على الفور إذا كنت تعاني من أي ألم مفاجئ أو صعوبة في التنفس أو احمرار في الجزء العلوي من الجسم أو طفح جلدي أو حكة.</p><p dir="RTL">امتصاص فانكومايسين من الجهاز الهضمي لا يكاد يذكر. ومع ذلك، إذا كنت تعاني من اضطراب في الجهاز الهضمي، أيضًا إذا كنت تعاني من اضطرابات في الكلى بشكل خاص، فقد تظهر الأعراض الجانبية التي تحدث عندما يتم إعطاء الفانكومايسين عن طريق الحقن.</p><p dir="RTL"><strong>الأعراض</strong><strong> </strong><strong>الجانبية ال</strong><strong>شائعة (قد يصيب ما يصل إلى شخصً واحدًا من كل 10 أشخاص): </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في ضغط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس، التنفس الصاخب (صوت عالي النبرة ناتج عن انسداد تدفق الهواء في مجرى الهواء العلوي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح والتهاب بطانة الفم والحكة والطفح الجلدي والشري</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الكلى التي قد يتم اكتشافها في المقام الأول عن طريق اختبارات الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الجزء العلوي من الجسم والوجه، التهاب الوريد</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة (قد تؤثر على ما يصل إلى 1 من كل 100 شخص):</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان مؤقت أو دائم للسمع</p><p dir="RTL"><strong>الآثار الجانبية النادرة (قد تؤثر على ما يصل إلى 1 من كل 1000 شخص):</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد خلايا الدم البيضاء وخلايا الدم الحمراء والصفائح الدموية (خلايا الدم المسؤولة عن تخثر الدم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في بعض الخلايا البيضاء في الدم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان التوازن، رنين في أذنيك، والدوخة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوعية الدموية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان (الشعور بالغثيان)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكلى والفشل الكلوي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في عضلات الصدر والظهر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى، قشعريرة</p><p dir="RTL"><strong>الآثار الجانبية النادرة جدا (قد تؤثر على ما يصل إلى 1 من كل 10000 شخص):</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور مفاجئ لرد فعل تحسسي شديد بالجلد مع ظهور تقرحات أو تقشير الجلد. قد يترافق هذا مع ارتفاع في درجة الحرارة وآلام المفاصل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السكتة القلبية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأمعاء الذي يسبب آلام البطن والإسهال، والتي قد تحتوي على الدم</p><p dir="RTL"><strong>غير معروف معدلاتها (لا يمكن تقدير معدلاتها من البيانات المتاحة):</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أن تكون مريضًا (الشعور بالإستلقاء) والإسهال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتباك، النعاس، قلة المجهود، التورم، احتباس السوائل، انخفاض كمية البول</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي مع تورم أو ألم خلف الأذنين، في الرقبة، الفخذ، تحت الذقن والإبطين (الغدد الليمفاوية المتورمة)، نتائج غير طبيعية لاختبارات الدم والكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح مع ظهور بثور وحمى.</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية: </strong></p><p dir="RTL">إذا زادت حدة أي من هذه الأعراض الجانبية، أو لاحظت ظهور أعراض جانبية غير ما تم ذكره في هذه النشرة، يرجى إبلاغ الطبيب المعالج أو الصيدلي. وهذا يشمل أي آثار جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضا الإبلاغ عن الآثار الجانبية مباشرة (انظر التفاصيل أدناه). بالإبلاغ عن الآثار الجانبية يمكنك المساعدة في توفير مزيد من المعلومات حول أمان هذا الدواء.</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:558px"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span dir=LTR></span><span
  dir=LTR></span><span dir=LTR><span dir=LTR></span><span dir=LTR></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span></span><![endif]--></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المركز الوطني للتيقظ والسلامة الدوائية</strong></p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; فاكس 7662-205-1-966+</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الاتصال على المركز الوطني للتيقظ والسلامة الدوائية +966-11-2038222، تحويلة: 2317-2356-2353-2354-2334-2340</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الهاتف المجاني: 8002490000</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني : npc.drug@sfda.gov.sa</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: www.sfda.gov.sa/npc</p></td></tr></tbody></table><!--[if mso & !supportInlineShapes & supportFields]><span
  dir=LTR><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:453.6pt;
   height:90.7pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span></span><![endif]--><p>&nbsp;</p><p dir="RTL"><strong>دول مجلس التعاون الخليجي الأخرى:</strong></p><p dir="RTL">&nbsp; &nbsp;يرجى الاتصال بالسلطة الصحية المختصة.</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ هذا الدواء عند درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ هذا الدواء في العبوة الأصلية للحماية من الرطوبة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ بعيدا عن متناول أيدي الأطفال أو على مرأى منهم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم فنكوسين فيال للحقن بعد انتهاء تاريخ الصلاحية المذكور على العبوة الخارجية. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر.</p><p dir="RTL"><strong>كيفية إعداد وتجهيز المحلول للتنقيط الوريدي:</strong></p><p dir="RTL"><strong>إعداد المحلول:</strong></p><p dir="RTL">في وقت الاستخدام، أضف 10 مل من الماء المعقم والمعد للحقن إلى قارورة فنكوسين المحتوية على 500 ملغم فانكومايسين. بالمثل، أضف 20 مل من الماء المعقم والمعد للحقن إلى قارورة فنكوسين المحتوية على 1 غرام من مسحوق فانكومايسين. وبذلك سيصبح تركيز المحلول في القوارير المعدة بهذه الطريقة إلى 50 ملغم / مل.</p><p dir="RTL">سيتطلب الأمر مزيد من التخفيف اعتمادا على طريقة الاستخدام:</p><p dir="RTL"><strong>(</strong><strong>i</strong><strong>) التسريب الوريدي المتقطع (الطريقة المفضلة للاستخدام):</strong></p><p dir="RTL">يجب تخفيف المحاليل التي تم حلها والتي تحتوي على 500 ملغم من الفانكومايسين باستخدام مادة مخففة لا تقل عن 100 مل. ويجب تخفيف المحاليل التي تم حلها والتي تحتوي على 1 جم من فانكومايسين باستخدام مادة مخففة لا تقل عن 200 مل.</p><p dir="RTL">محلول كلوريد الصوديوم للحقن عن طريق الوريد أو محلول ديكستروز 5 ٪ للحقن عن طريق الوريد هي مخففات مناسبة. يجب أن تستخدم الجرعة المطلوبة بالتسريب في الوريد لمدة 60 دقيقة على الأقل. إذا تم تناوله على فترة زمنية أقصر أو بتركيزات أعلى، فهناك احتمال إحداث انخفاض ملحوظ في ضغط الدم بالإضافة إلى التهاب الوريد الخثاري.</p><p dir="RTL">قد يؤدي الحقن بمعدل سريع إلى حدوث طفح وطفح عابر فوق الرقبة والكتفين.</p><p dir="RTL"><strong>(</strong><strong>ii</strong><strong>) التسريب الوريدي المستمر (يجب استخدامه فقط عندما لا يكون التسريب المتقطع ممكنًا):</strong></p><p dir="RTL">يمكن إضافة 1 غم أو 2 غم من فانكومايسين إلى كمية كبيرة بما يكفي من محلول التسريب الوريدي لكلوريد الصوديوم أو محلول ديكستروز 5 ٪ المعد للحقن الوريدي وذلك للسماح بأن تستمر الجرعة المطلوبة لمدة خلال أربع وعشرين ساعة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong style="text-align:unset">ما تحتويه فنكوسين فيال للحقن</strong></p><p dir="RTL">المادة الفعالة هي فانكومايسين هيدروكلوريد.</p><p dir="RTL"><strong>فنكوسين فيال للحقن 500 ملغم المتوافق مع دستور الأدوية الأمريكي</strong></p><p dir="RTL">تحتوي كل قارورة على فانكومايسين هيدروكلوريد ما يكافئ 500 ملغم فانكومايسين</p><p dir="RTL"><strong>الصواغات الأخرى هي</strong>: هيدروكسيد الصوديوم، حمض الهيدروكلوريك، الماء المعد للحقن</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong><u>فنكوسين فيال للحقن 500 ملغم المتوافق مع دستور الأدوية الأمريكي</u></strong></p><p dir="RTL">مسحوق مجفف بالتبريد لونه أبيض إلى تان (لون البشرة الغامق)، المسحوق موجودة في قارورة زجاجية شفافة من النوع الأول سعة 20 مل ومتوافقة مع دستور الأدوية الأمريكي مع سدادة مطاطية رمادية اللون 20 ملم من البروموبيوتيل وسداده أمان 20 ملم لونها أزرق سماوي.</p><p dir="RTL">عند إعادة الحل وفقًا للتوجيهات، يجب أن يكون المحلول نقي ومحلولًا بلون فاتح إلى التان.</p><p dir="RTL"><strong>توافر فنكوسين فيال للحقن:</strong></p><p dir="RTL">يتوافر فنكوسين في فيال للحقن (قارورة زجاجية).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شركة أماروكس السعودية للصناعة</strong></p><p dir="RTL">شارع الجامعة &ndash; الملز &ndash; الرياض 11441</p><p dir="RTL">المملكة العربية السعودية.</p><p dir="RTL">تليفون: &nbsp;+ 966 114772215</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            8/2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vancomycin Hydrochloride for Injection USP 500mg/Vial 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vancomycin Hydrochloride for Injection USP 500mg/Vial: 
Each vial contains Vancomycin hydrochloride USP equivalent to vancomycin 500mg 
 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vancomycin Hydrochloride for Injection USP 500mg/Vial: 
White to tan lyophilized cake or powder present in 20 mL clear USP Type I glass vial with 20mm grey bromobutyl lyophilization rubber stopper and 20mm flip off seal. 
When reconstituted as directed the solution should be clear, light to dark tan colored solution. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Intravenous administration</u>&nbsp; Vancomycin is indicated in all age groups for the treatment of the following infections (see sections 4.2, 4.4 and 5.1):</p><p>-&nbsp; complicated skin and soft tissue infections (cSSTI)</p><p>-&nbsp; bone and joint infections</p><p>-&nbsp; community acquired pneumonia (CAP)</p><p>-&nbsp; hospital acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP)</p><p>-&nbsp; infective endocarditis</p><p>-&nbsp; acute bacterial meningitis</p><p>-&nbsp; bacteremia that occurs in association with, or is suspected to be associated with, any of the above.</p><p>Vancomycin is also indicated in all age groups for the perioperative antibacterial prophylaxis in patients that are at high risk of developing bacterial endocarditis when undergoing major surgical procedures.</p><p>Oral administration&nbsp;</p><p>Vancomycin is indicated in all age groups for the treatment of Clostridium difficile infection (CDI) (see sections 4.2, 4.4 and 5.1).</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>Where appropriate, vancomycin should be administered in combination with other antibacterial agents.</p><p>&nbsp;</p><p>Intravenous administration&nbsp;</p><p>The initial dose should be based on total body weight. Subsequent dose adjustments should be based on serum concentrations to achieve targeted therapeutic concentrations. Renal function must be taken into consideration for subsequent doses and interval of administration.</p><p>Patients aged 12 years and older&nbsp;</p><p>The recommended dose is 15 to 20 mg/kg of body weight every 8 to 12 h (not to exceed 2 g per dose). In seriously ill patients, a loading dose of 25&ndash;30 mg/kg of body weight can be used to facilitate rapid attainment of target trough serum vancomycin concentration.</p><p><u>Infants and children aged from one month to less than 12 years of age:</u>&nbsp;</p><p>The recommended dose is 10 to 15 mg/kg body weight every 6 hours (see section 4.4).</p><p>Term neonates (from birth to 27 days of post-natal age) and preterm neonates (from birth to the expected date of delivery plus 27 days)&nbsp;</p><p>For establishing the dosing regimen for neonates, the advice of a physician experienced in the management of neonates should be sought. One possible way of dosing vancomycin in neonates is illustrated in the following table: (see section 4.4)</p><table border="0" cellspacing="0" cellpadding="0" style="width:420px"><tbody><tr><td style="vertical-align:top"><p><strong>PMA (weeks)</strong></p></td><td style="vertical-align:top"><p><strong>Dose (mg/kg)</strong></p></td><td style="vertical-align:top"><p><strong>Interval of administration (h)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&lt;29</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>24</p></td></tr><tr><td style="vertical-align:top"><p>29-35</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>12</p></td></tr><tr><td style="vertical-align:top"><p>&gt;35</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>8</p></td></tr></tbody></table><p>PMA: post-menstrual age [(time elapsed between the first day of the last menstrual period and birth (gestational age) plus the time elapsed after birth (post-natal age)]. Peri-operative prophylaxis of bacterial endocarditis in all age groups&nbsp;</p><p>The recommended dose is an initial dose of 15 mg/kg prior to induction of anesthesia. Depending on the duration of surgery, a second vancomycin dose may be required.</p><p>Duration of treatment&nbsp;</p><p>Suggested treatment duration is shown in table below. In any case, the duration of treatment should be tailored to the type and severity of infection and the individual clinical response.</p><table border="0" cellspacing="0" cellpadding="0" style="width:607px"><tbody><tr><td style="vertical-align:top"><p>Indication</p></td><td style="vertical-align:top"><p>Treatment Duration</p></td></tr><tr><td style="vertical-align:top"><p>Complicated skin and soft tissue infections</p><p>-Non necrotizing</p><p>-Necrotizing</p></td><td style="vertical-align:top"><p>7 to 14 days</p><p>4 to 6 weeks*</p></td></tr><tr><td style="vertical-align:top"><p>Bone and joint infections</p></td><td style="vertical-align:top"><p>4 to 6 weeks**</p></td></tr><tr><td style="vertical-align:top"><p>Community-aquired pneumonia</p></td><td style="vertical-align:top"><p>7 to 14 days</p></td></tr><tr><td style="vertical-align:top"><p>Hospital acquired pneumonia, including ventilatorassociated pneumonia</p></td><td style="vertical-align:top"><p>7 to 14 days</p></td></tr><tr><td style="vertical-align:top"><p>Infective endocarditis</p></td><td style="vertical-align:top"><p>4 to 6 weeks***</p></td></tr><tr><td style="vertical-align:top"><p>Acute bacterial meningitis&nbsp;</p></td><td style="vertical-align:top"><p>10 to 21 days</p></td></tr></tbody></table><p>*Continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours</p><p>**Longer courses of oral suppression treatment should be considered for prosthetic joint infections</p><p>***Duration and need for combination therapy is based on valve-type and organism.</p><p>Special populations&nbsp; <em>Elderly</em>&nbsp;</p><p>Lower maintenance doses may be required due to the age-related reduction in renal function.</p><p><em>Renal impairment</em>&nbsp;</p><p>In adult and paediatric patients with renal impairment, consideration should be given to an initial starting dose followed by serum vancomycin trough levels rather than to a scheduled dosing regimen, particularly in patients with severe renal impairment or those who undergo renal replacement therapy (RRT) due to the many varying factors that may affect vancomycin levels in them.</p><p>In patients with mild or moderate renal failure, the starting dose must not be reduced. In patients with severe renal failure, it is preferable to prolong the interval of administration rather than administer lower daily doses.</p><p>Appropriate consideration should be given to the concomitant administration of medicinal products that may reduce vancomycin clearance and/or potentiate its undesirable effects (see section 4.4).</p><p>Vancomycin is poorly dialyzable by intermittent hemodialysis. However, use of high-flux membranes and continuous renal replacement therapy (CRRT) increases vancomycin clearance and generally requires replacement dosing (usually after the haemodialysis session in case of intermittent haemodialysis).</p><p><em>Adults</em>&nbsp;</p><p>Dose adjustments in adult patients could be based on glomerular filtration rate estimated (eGFR) by the following formula:</p><p>Men: [Weight (kg) x 140 - age (years)]/ 72 x serum creatinine (mg/dl) Women: 0.85 x value calculated by the above formula.</p><p>The usual starting dose for adult patients is 15 to 20 mg/kg that could be administered every 24 hours in patients with creatinine clearance between 20 to 49 ml/min. In patients with severe renal impairment (creatinine clearance below 20 ml/min) or those on renal replacement therapy, the appropriate timing and amount of subsequent doses largely depend on the modality of RRT and should be based on serum vancomycin trough levels and on residual renal function (see section 4.4). Depending on the clinical situation, consideration could be given to withhold the next dose while awaiting the results of vancomycin levels.</p><p>In the critically ill patient with renal insufficiency, the initial loading dose (25 to 30 mg/kg) should not be reduced. <em>Paediatric population</em>&nbsp;</p><p>Dose adjustments in paediatric patients aged 1 year and older could be based on glomerular filtration rate estimated (eGFR) by the revised Schwartz formula:</p><p>eGFR (mL/min/1.73m<sup>2</sup> ) = (height cm x 0.413)/ serum creatinine (mg/dl) eGFR (mL/min/1.73m<sup>2</sup>)= (height cm x 36.2/serum creatinine (&mu;mol/L)</p><p>For neonates and infants below 1 year of age, expert advice should be sought as the revised Schwartz formula is not applicable to them.</p><p>Orientative dosing recommendations for the paediatric population are shown in table below that follow the same principles as in adult patients.</p><table border="0" cellspacing="0" cellpadding="0" style="width:607px"><tbody><tr><td style="vertical-align:top"><p><strong>GFR (mL/min/1.73 m<sup>2</sup>)</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>IV dose</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Frequency</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>50-30</p></td><td style="vertical-align:top"><p>15 mg/kg</p></td><td style="vertical-align:top"><p>12 hourly</p></td></tr><tr><td style="vertical-align:top"><p>29-10</p></td><td style="vertical-align:top"><p>15 mg/kg</p></td><td style="vertical-align:top"><p>24 hourly</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 10</p></td><td rowspan="3" style="vertical-align:top"><p>10-15 mg/kg</p></td><td rowspan="3" style="vertical-align:top"><p>Re-dose based on levels*</p></td></tr><tr><td style="vertical-align:top"><p>Intermittent haemodialysis</p></td></tr><tr><td style="vertical-align:top"><p>Peritoneal dialysis</p></td></tr><tr><td style="vertical-align:top"><p>Continuous renal replacement therapy</p></td><td style="vertical-align:top"><p>15 mg/kg</p></td><td style="vertical-align:top"><p>Re-dose based on levels*</p></td></tr></tbody></table><p>*The appropriate timing and amount of subsequent doses largely depends on the modality of RRT and should be based on serum vancomycin levels obtained prior to dosing and on residual renal function. Depending on the clinical situation, consideration could be given to withhold the next dose while awaiting the results of vancomycin levels.</p><p><em><u>Hepatic impairment:</u> </em>&nbsp;</p><p>No dose adjustment is needed in patients with hepatic insufficiency.</p><p><em><u>Pregnancy</u></em>&nbsp;</p><p>Significantly increased doses may be required to achieve therapeutic serum concentrations in pregnant women (see Section 4.6).</p><p><em><u>Obese patients</u> </em>&nbsp;</p><p>In obese patients, the initial dose should be individually adapted according to total body weight as in non-obese patients.</p><p>Therapeutic trough (minimum) vancomycin blood levels should normally be 10-20 mg/l, depending on the site of infection and susceptibility of the pathogen. Trough values of 15-20 mg/l are usually recommended by clinical laboratories to better cover susceptible pathogens with</p><p>MIC &ge;1 mg/L (see sections 4.4 and 5.1).</p><p>Model-based methods may be useful in the prediction of individual dose requirements to reach an adequate AUC. The model-based approach can be used both in calculating the personalized starting dose and for dose adjustments based on TDM results (see section 5.1).</p><p>Method of administration&nbsp;</p><p><u>Intravenous administration</u> : Intravenous vancomycin is usually administered as an intermittent infusion and the dosing recommendations presented in this section for the intravenous route correspond to this type of administration.</p><p>Vancomycin shall only be administered as slow intravenous infusion of at least one hour duration or at a maximum rate of 10 mg/min (whichever is longer) which is sufficiently diluted (at least 100 ml per 500 mg or at least 200 ml per 1000 mg) (see section 4.4).</p><p>Patients whose fluid intake must be limited can also receive a solution of 500 mg/50 ml or 1000 mg/100 ml, although the risk of infusion-related undesirable effects can be increased with these higher concentrations.</p><p>For information about the preparation of the solution, please see section 6.6.</p><p>Continuous vancomycin infusion may be considered, e.g., in patients with unstable vancomycin clearance.</p><p>Information on reconstitution and dilution of the medicinal product before use, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 (see section 4.4).
Vancomycin should not be administered intramuscularly due to the risk of necrosis at the site of administration.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypersensitivity reactions</u>&nbsp;</p><p>Serious and occasionally fatal hypersensitivity reactions are possible (see sections 4.3 and 4.8). In case of hypersensitivity reactions, treatment with vancomycin must be discontinued immediately and the adequate emergency measures must be initiated.</p><p>In patients receiving vancomycin over a longer-term period or concurrently with other medications which may cause neutropenia or agranulocytosis, the leukocyte count should be monitored at regular intervals. All patients receiving vancomycin should have periodic hematologic studies, urine analysis, liver and renal function tests.</p><p>Vancomycin should be used with caution in patients with allergic reactions to teicoplanin, since cross hypersensitivity, including fatal anaphylactic shock, may occur.</p><p>Spectrum of antibacterial activity&nbsp;</p><p>Vancomycin has a spectrum of antibacterial activity limited to Gram-positive organisms. It is not suitable for use as a single agent for the treatment of some types of infections unless the pathogen is already documented and known to be susceptible or there is a high suspicion that the most likely pathogen(s) would be suitable for treatment with vancomycin.</p><p>The rational use of vancomycin should take into account the bacterial spectrum of activity, the safety profile and the suitability of standard antibacterial therapy to treat the individual patient.</p><p>Ototoxicity&nbsp;</p><p>Ototoxicity, which may be transitory or permanent (see section 4.8) has been reported in patients with prior deafness, who have received excessive intravenous doses, or who receive concomitant treatment with another ototoxic active substance such as an aminoglycoside. Vancomycin should also be avoided in patients with previous hearing loss. Deafness may be preceded by tinnitus. Experience with other antibiotics suggests that deafness may be progressive despite cessation of treatment. To reduce the risk of ototoxicity, blood levels should be determined periodically and periodic testing of auditory function is recommended.</p><p>The elderly are particularly susceptible to auditory damage. Monitoring of vestibular and auditory function in the elderly should be carried out during and after treatment. Concurrent or sequential use of other ototoxic substances should be avoided.</p><p>Infusion-related reactions&nbsp;</p><p>Rapid bolus administration (i.e. over several minutes) may be associated with exaggerated hypotension (including shock and, rarely, cardiac arrest), histamine like responses and maculopapular or erythematous rash (&ldquo;red man&#39;s syndrome&rdquo; or &ldquo;red neck syndrome&rdquo;). Vancomycin should be infused slowly in a dilute solution (2.5 to 5.0 mg/ml) at a rate no greater than 10 mg/min and over a period not less than 60 minutes to avoid rapid infusion-related reactions. Stopping the infusion usually results in a prompt cessation of these reactions.</p><p>The frequency of infusion-related reactions (hypotension, flushing, erythema, urticaria and pruritus) increases with the concomitant administration of anaesthetic agents (see section 4.5). This may be reduced by administering vancomycin by infusion over at least 60 minutes, before anaesthetic induction.</p><p>Severe bullous reactions&nbsp;</p><p>Stevens-Johnson syndrome (SJS) has been reported with the use of vancomycin (see section 4.8). If symptoms or signs of SJS (e.g. progressive skin rash often with blisters or mucosal lesions) are present, vancomycin treatment should be discontinued immediately and specialised dermatological assessment be sought. Administration site related reactions&nbsp;</p><p>Pain and thrombophlebitis may occur in many patients receiving intravenous vancomycin and are occasionally severe. The frequency and severity of thrombophlebitis can be minimized by administering the medicinal product slowly as a dilute solution (see section 4.2) and by changing the sites of infusion regularly.</p><p>The efficacy and safety of vancomycin has not been established for the intrathecal, intralumbar and intraventricular routes of administration.</p><p><u>Nephrotoxicity </u>: Vancomycin should be used with care in patients with renal insufficiency, including anuria, as the possibility of developing toxic effects is much higher in the presence of prolonged high blood concentrations. The risk of toxicity is increased by high blood concentrations or prolonged therapy.</p><p>Regular monitoring of the blood levels of vancomycin is indicated in high dose therapy and longer-term use, particularly in patients with renal dysfunction or impaired faculty of hearing as well as in concurrent administration of nephrotoxic or ototoxic substances, respectively (see section 4.2).</p><p>Paediatric population&nbsp;</p><p>The current intravenous dosing recommendations for the paediatric population, in particular for children below 12 years of age, may lead to sub-therapeutic vancomycin levels in a substantial number of children. However, the safety of increased vancomycin dosing has not been properly assessed and higher doses than 60 mg/kg/day cannot be generally recommended.</p><p>Vancomycin should be used with particular care in premature neonates and young infants, because of their renal immaturity and the possible increase in the serum concentration of vancomycin. The blood concentrations of vancomycin should therefore be monitored carefully in these children. Concomitant administration of vancomycin and anaesthetic agents has been associated with erythema and histamine-like flushing in children. Similarly, concomitant use with nephrotoxic agents such as aminoglycoside antibiotics, NSAIDs (e.g., ibuprofen for closure of patent ductus arteriosus) or amphotericin B is associated with an increased risk of nephrotoxicity (see section 4.5) and therefore more frequent monitoring of vancomycin serum levels and renal function is indicated.</p><p>Use in the elderly&nbsp;</p><p>The natural decrement of glomerular filtration with increasing age may lead to elevated vancomycin serum concentrations if dosage is not adjusted (see section 4.2).</p><p>Drug interactions with anesthetic agents&nbsp;</p><p>Anaesthetic induced myocardial depression may be enhanced by vancomycin. During anaesthesia, doses must be well diluted and administered slowly with close cardiac monitoring. Position changes should be delayed until the infusion is completed to allow for postural adjustment (see section 4.5).</p><p>Pseudomembranous enterocolitis&nbsp;</p><p>In case of severe persistent diarrhoea the possibility of pseudomembranous enterocolitis that might be life-threatening has to be taken into account (see section 4.8). Anti-diarrhoeic medicinal products must not be given. <u>Superinfection</u>&nbsp;</p><p>Prolonged use of vancomycin may result in the overgrowth of non-susceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.</p><p>Oral administration&nbsp;</p><p>Intravenous administration of vancomycin is not effective for the treatment of Clostridium difficile infection. Vancomycin should be administered orally for this indication.</p><p>Testing for Clostridium difficile colonization or toxin is not recommended in children younger than 1 year due to high rate of asymptomatic colonisation unless severe diarrhoea is present in infants with risk factors for stasis such as Hirschsprung disease, operated anal atresia or other severe motility disorders. Alternative aetiologies should always be sought and Clostridium difficile enterocolitis be proven.</p><p>Potential for Systemic Absorption&nbsp;</p><p>Absorption may be enhanced in patients with inflammatory disorders of the intestinal mucosa or with Clostridium difficile-induced pseudomembranous colitis. These patients may be at risk for the development of adverse reactions, especially if there is a concomitant renal impairment. The greater the renal impairment, the greater the risk of developing the adverse reactions associated with the parenteral administration of vancomycin. Monitoring of serum vancomycin concentrations of patients with inflammatory disorders of the intestinal mucosa should be performed.</p><p>Nephrotoxicity&nbsp;</p><p>Serial monitoring of renal function should be performed when treating patients with underlying renal dysfunction or patients receiving concomitant therapy with an aminoglycoside or other nephrotoxic drugs.</p><p>Ototoxicity&nbsp;</p><p>Serial tests of auditory function may be helpful in order to minimise the risk of ototoxicity in patients with an underlying hearing loss, or who are receiving concomitant therapy with an ototoxic agent such as an aminoglycoside.</p><p><u>Drug interactions with anti-motility agents and proton pump inhibitors</u>&nbsp;&nbsp;</p><p>Anti-motility agents should be avoided and proton pump inhibitor use should be reconsidered.</p><p>Development of Drug-Resistant Bacteria&nbsp;</p><p>Oral vancomycin use increases the chance of vancomycin-resistant Enterococci populations in the gastrointestinal tract. As a consequence, prudent use of oral vancomycin is advised.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concurrent administration of vancomycin and anaesthetic agents has been associated with erythema, histamine like flushing and anaphylactoid reactions.</p><p>Concurrent administration with other neurotoxic or nephrotoxic drugs, e.g. amphotericin B, streptomycin, neomycin, gentamicin, kanamycin, amikacin, tobramycin, bacitracin, polymyxin B, colistin and cisplatin requires careful monitoring.</p><p>Diuretics such as ethacrynic acid and frusemide may aggravate ototoxicity.</p><p>Cholestyramine has been shown to bind vancomycin in-vitro. Therefore, if oral Vancomycin is used with cholestyramine, the two drugs should be administered several hours apart.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Use in Pregnancy:</u> </strong>&nbsp;</p><p>Teratology studies have been performed at 5 times the human dose in rats and 3 times the human dose in rabbits, and have revealed no evidence of harm to the foetus due to vancomycin. In a controlled clinical study, the potential ototoxic and nephrotoxic effects of vancomycin hydrochloride on infants were evaluated when the drug was administered to pregnant women for serious staphylococcal infections complicating intravenous drug abuse. Vancomycin hydrochloride was found in cord blood. No sensorineural hearing loss or nephrotoxicity attributable to vancomycin was noted.&nbsp;</p><p>One infant, whose mother received vancomycin in the third trimester, experienced conductive hearing loss that was not attributable to vancomycin. Because vancomycin was administered only in the second and third trimesters, it is not known whether it causes foetal harm. Vancomycin should be given in pregnancy only if clearly needed and blood levels should be monitored carefully to minimise the risk of foetal toxicity. It has been reported, however, that pregnant patients may require significantly increased doses of vancomycin to achieve therapeutic serum concentrations.</p><p><strong><u>Use in Lactation:</u> </strong>&nbsp;</p><p>Vancomycin Hydrochloride is excreted in breast milk but it is not known whether it is harmful to the newborn. Therefore, it is not recommended for nursing mothers unless the expected benefits outweigh any potential risk.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the Safety profile&nbsp;</p><p>The most common adverse reactions are phlebitis, pseudo-allergic reactions and flushing of the upper body (&ldquo;red-neck syndrome&rdquo;) in connection with too rapid intravenous infusion of vancomycin.</p><p>The absorption of vancomycin from the gastrointestinal tract is negligible. However, in severe inflammation of the intestinal mucosa, especially in combination with renal insufficiency, adverse reactions that occur when vancomycin is administered parenterally may appear.</p><p>Tabulated List of Adverse reactions&nbsp;</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>The adverse reactions listed below are defined using the following MedDRA convention and system organ class database: Very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon</p><p>(&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><table border="0" cellspacing="0" cellpadding="0" style="width:635px"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Frequency</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and the lymphatic system disorders:</strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Reversible &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; neutropenia, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; agranulocytosis, eosinophilia, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thrombocytopenia, pancytopenia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders: </strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Hypersensitivity &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reactions, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anaphylactic reactions</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders:</strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Transient or permanent loss of hearing</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:635px"><tbody><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Vertigo, tinnitus, dizziness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Cardiac arrest</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders:</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Decrease in blood pressure</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Vasculitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders:</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dyspnoea, stridor</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders:</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Nausea</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Pseudomembranous enterocolitis</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Vomiting, Diarrhoea</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders:</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Flushing of the upper body (&ldquo;red man syndrome&rdquo;), exanthema and mucosal</p><p>inflammation, pruritus, urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Exfoliative dermatitis, Stevens-Johnson syndrome, Lyell&#39;s syndrome, Linear IgA bullous dermatosis</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Eosinophilia and systemic symptoms (DRESS syndrome), AGEP (Acute</p><p>Generalized Exanthematous Pustulosis)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders:</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Renal insufficiency manifested primarily by increased serum creatinine and serum urea</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Interstitial nephritis, acute renal failure.</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Acute tubular necrosis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions:</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Phlebitis, redness of the upper body and face.</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Drug fever, shivering, pain and muscle spasm of the chest and back muscles</p></td></tr></tbody></table><p>Description of selected adverse drug reactions&nbsp;</p><p>Reversible neutropenia usually starting one week or more after onset of intravenous therapy or after total dose of more than 25 g.</p><p>During or shortly after rapid infusion anaphylactic/anaphylactoid reactions including wheezing may occur. The reactions abate when administration is stopped, generally between 20 minutes and 2 hours. Vancomycin should be infused slowly (see sections 4.2 and 4.4). Necrosis may occur after intramuscular injection.</p><p>Tinnitus, possibly preceding onset of deafness, should be regarded as an indication to discontinue treatment.</p><p>Ototoxicity has primarily been reported in patients given high doses, or in those on concomitant treatment with other ototoxic medicinal product like aminoglycoside, or in those who had a preexisting reduction in kidney function or hearing.</p><p>If a bullous disorder is suspected, the drug should be discontinued and specialised dermatological assessment should be carried out.</p><p>Paediatric population&nbsp;</p><p>The safety profile is generally consistent among children and adult patients. Nephrotoxicity has been described in children, usually in association with other nephrotoxic agents such as aminoglycosides.</p><p><strong><u>Reporting of suspected adverse reactions&nbsp;</u></strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects&nbsp;&nbsp;&nbsp; not listed in this leaflet. You can also report side effects directly (see details below). By reporting side affects; you can help provide more information on the safety of this medicine.</p><p><strong><em>&bull; </em>Saudi Arabia<em>:</em></strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:512px"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (SFDA)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p><strong><em>Other GCC States:</em></strong><br />Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Supportive care is advised, with maintenance of glomerular filtration. Vancomycin is poorly removed from the blood by haemodialysis or peritoneal dialysis. Haemoperfusion with Amberlite resin XAD-4 has been reported to be of limited benefit.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Anti-infective for systemic use&nbsp;</p><p>Therapeutic subgroup: Antibacterial for systemic use</p><p>Pharmacological subgroup: Other antibacterial</p><p>Chemical subgroup: Glycopeptide antibacterial</p><p>ATC Code: J01X01</p><p>Mechanism of action&nbsp;</p><p>Vancomycin is a tricyclic glycopeptide antibiotic that inhibits the synthesis of the cell wall in sensitive bacteria by binding with high affinity to the D-alanyl-D-alanine terminus of cell wall precursor units. The drug is slowly bactericidal for dividing microorganisms. In addition, it impairs the permeability of the bacterial cell membrane and RNA synthesis.</p><p>Pharmacokinetic/ Pharmacodynamic relationship&nbsp;</p><p>Vancomycin displays concentration-independent activity with the area under the concentration curve (AUC) divided by the minimum inhibitory concentration (MIC) of the target organism as the primary predictive parameter for efficacy. On basis of in vitro, animal and limited human data, an AUC/MIC ratio of 400 has been established as a PK/PD target to achieve clinical effectiveness with vancomycin. To achieve this target when MICs are &ge; 1.0 mg/l, dosing in the upper range and high trough serum concentrations (15-20 mg/l) are required (see section 4.2).</p><p>Mechanism of resistance&nbsp;</p><p>Acquired resistance to glycopeptides is most common in enterococci and is based on acquisition of various van gene complexes which modifies the D-alanyl-D-alanine target to D-alanyl-Dlactate or D-alanyl-D-serine which bind vancomycin poorly. In some countries, increasing cases of resistance are observed particularly in enterococci; multi-resistant strains of Enterococcus faecium are especially alarming.</p><p>Van genes have rarely been found in Staphylococcus aureus, where changes in cell wall structure result in &ldquo;intermediate&rdquo; susceptibility, which is most commonly heterogeneous. Also, methicillin-resistant staphylococcus strains (MRSA) with reduced susceptibility for vancomycin were reported. The reduced susceptibility or resistance to vancomycin in Staphylococcus is not well understood. Several genetic elements and multiple mutations are required.</p><p>There is no cross-resistance between vancomycin and other classes of antibiotics. Crossresistance with other glycopeptide antibiotics, such as teicoplanin, does occur. Secondary development of resistance during therapy is rare.</p><p>Synergism&nbsp;</p><p>The combination of vancomycin with an aminoglycoside antibiotic has a synergistic effect against many strains of Staphylococcus aureus, non-enterococcal group D-streptococci, enterococci and streptococci of the Viridans group. The combination of vancomycin with a cephalosporin has a synergistic effect against some oxacillin-resistant Staphylococcus epidermidis strains, and the combination of vancomycin with rifampicin has a synergistic effect against Staphylococcus epidermidis and a partial synergistic effect against some Staphylococcus aureus strains. As vancomycin in combination with a cephalosporin may also have an antagonistic effect against some Staphylococcus epidermidis strains and in combination with rifampicin against some Staphylococcus aureus strains, preceding synergism testing is useful.</p><p>Specimens for bacterial cultures should be obtained in order to isolate and identify the causative organisms and to determine their susceptibility to vancomycin.</p><p>Susceptibility testing breakpoints&nbsp;</p><p>Vancomycin is active against gram-positive bacteria, such as staphylococci, streptococci, enterococci, pneumococci, and clostridia. Gram-negative bacteria are resistant.</p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable. This information only provides approximate guidance on the chance whether micro-organisms are susceptible to vancomycin.</p><p>Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are as follows:</p><table border="0" cellspacing="0" cellpadding="0" style="width:645px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Susceptible</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Resistant</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus aureus</em><sup>1</sup>&nbsp;</p></td><td style="vertical-align:top"><p>&le; 2 mg/L</p></td><td style="vertical-align:top"><p>&gt; 2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p>Coagulase-negative staphylococci<sup>1</sup></p></td><td style="vertical-align:top"><p>&le; 4 mg/L</p></td><td style="vertical-align:top"><p>&gt; 4 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Enterococcus </em>spp.</p></td><td style="vertical-align:top"><p>&le; 4 mg/L</p></td><td style="vertical-align:top"><p>&gt; 4 mg/L</p></td></tr><tr><td style="vertical-align:top"><p>Streptococcus groups A, B, C and G</p></td><td style="vertical-align:top"><p>&le; 2 mg/L</p></td><td style="vertical-align:top"><p>&gt; 2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pneumoniae</em>&nbsp;</p></td><td style="vertical-align:top"><p>&le; 2 mg/L</p></td><td style="vertical-align:top"><p>&gt; 2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p>Gram positive anaerobes</p></td><td style="vertical-align:top"><p>&le; 2 mg/L</p></td><td style="vertical-align:top"><p>&gt; 2 mg/L</p></td></tr></tbody></table><p><sup>1 </sup><em>S. aureus</em> with vancomycin MIC values of 2 mg/L are on the border of the wild type distribution and there may be an impaired clinical response.</p><table border="0" cellspacing="0" cellpadding="0" style="width:645px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong><u>Commonly susceptible species</u> </strong>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gram positive </strong>&nbsp;</p><p>Enterococcus faecalis&nbsp;</p><p>Staphylococcus aureus&nbsp;</p><p>Methicillin-resistant Staphylococcus aureus coagulase-negative Staphylococci&nbsp; Streptococcus spp.&nbsp;</p><p>Streptococcus pneumoniae&nbsp; Enteroccocus spp.&nbsp;</p><p>Staphylococcus spp.&nbsp;</p><p><strong>Anaerobic species </strong>&nbsp;</p><p>Clostridium spp. except Clostridium&nbsp;</p><p>innocuum&nbsp;</p><p>Eubacterium spp.&nbsp;</p><p>Peptostreptococcus spp.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><u>Species for which acquired resistance may be a problem</u> </strong>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Enterococcus faecium&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><u>Inherently resistant</u> </strong>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>All Gram negative bacteria </strong>&nbsp;</p><p><strong>Gram positive aerobic species </strong>Erysipelothrix rhusiopathiae, Heterofermentative Lactobacillus, Leuconostoc spp&nbsp; Pediococcus spp.&nbsp;</p><p><strong>Anaerobic species</strong>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Clostridium innocuum&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>The emergence of resistance towards vancomycin differs from one hospital to another and a local microbiological laboratory should therefore be contacted for relevant local information.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u>&nbsp;</p><p>Vancomycin is administered intravenously for the treatment of systemic infections.&nbsp;</p><p>In the case of patients with normal renal function, intravenous infusion of multiple doses of 1g vancomycin (15 mg/kg) for 60 minutes produces approximate average plasma concentrations of 50-60 mg/L, 20-25 mg/L and 5-10 mg/L, immediately, 2 hours and 11 hours after completing the infusion, respectively. The plasma levels obtained after multiple doses are similar to those achieved after a single dose.</p><p>Vancomycin is not usually absorbed into the blood after oral administration. However, absorption may occur after oral administration in patients with (pseudomembranous) colitis. This may lead to vancomycin accumulation in patients with co-existing renal impairment.</p><p>Distribution&nbsp;</p><p>The volume of distribution is about 60 L/1.73 m<sup>2 </sup>body surface. At serum concentrations of vancomycin of 10 mg/l to 100 mg/l, the binding of the drug to plasma proteins is approximately 30-55%, measured by ultra-filtration.</p><p>Vancomycin diffuses readily across the placenta and is distributed into cord blood. In noninflamed meninges, vancomycin passes the blood-brain barrier only to a low extent.</p><p>Biotransformation&nbsp;</p><p>There is very little metabolism of the drug. After parenteral administration it is excreted almost completely as microbiologically active substance (approx. 75-90% within 24 hours) through glomerular filtration via the kidneys.</p><p>Elimination&nbsp;</p><p>The elimination half-life of vancomycin is 4 to 6 hours in patients with normal renal function and</p><p>2.2-3 hours in children. Plasma clearance is about 0.058 L/kg/h and kidney clearance about 0.048 L/kg/h. In the first 24 hours, approximately 80 % of an administered dose of vancomycin is excreted in the urine through glomerular filtration. Renal dysfunction delays the excretion of vancomycin. In anephric patients, the mean half-life is 7.5 days. Due to ototoxicity of vancomycin therapy-adjuvant monitoring of the plasma concentrations is indicated in such cases. Biliary excretion is insignificant (less than 5% of a dose).</p><p>Although the vancomycin is not eliminated efficiently by haemodialysis or peritoneal dialysis, there have been reports of an increase in vancomycin clearance with haemoperfusion and haemofiltration.</p><p>After oral administration, only a fraction of the administered dose is recovered in the urine. In contrast, high concentrations of vancomycin are found in the faeces (&gt;3100 mg/kg with doses of 2 g/day).</p><p>Linerarity/non-linearity&nbsp;</p><p>Vancomycin concentration generally increases proportionally with increasing dose. Plasma concentrations during multiple dose administration are similar to those after the administration of a single dose.</p><p>Characteristics in specific groups&nbsp;</p><p><em>Renal impairment</em>&nbsp;</p><p>Vancomycin is primarily cleared by glomerular filtration. In patients with impaired renal function the terminal elimination half- life of vancomycin is prolonged and the total body clearance is reduced. Subsequently, optimal dose should be calculated in line with dosing recommendations provided in section 4.2. <em>Hepatic impairment</em>&nbsp;</p><p>Vancomycin pharmacokinetics is not altered in patients with hepatic impairment.</p><p><em>Pregnant Women:</em>&nbsp;</p><p>Significantly increased doses may be required to achieve therapeutic serum concentrations in pregnant women (see Section 4.6). <em>Overweight patients</em>&nbsp;</p><p>Vancomycin distribution may be altered in overweight patients due to increases in volume of distribution, in renal clearance and possible changes in plasma protein binding. In these subpopulations vancomycin serum concentration were found higher than expected in male healthy adults (see section 4.2).</p><p>Paediatric population&nbsp;</p><p>Vancomycin PK has shown wide inter-individual variability in preterm and term neonates. In neonates, after intravenous administration, vancomycin volume of distribution varies between 0.38 and 0.97 L/kg, similar to adult values, while clearance varies between 0.63 and 1.4 ml/kg/min. Half-life varies between 3.5 and 10 h and is longer than in adults, reflecting the usual lower values for clearance in the neonate.</p><p>In infants and older children, the volume of distribution ranges between 0.26-1.05 L/kg while clearance varies between 0.33-1.87 ml/kg/min.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The other ingredients are: Sodium hydroxide, Hydrochloric acid, Water for Injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vancomycin solution has a low pH that may cause chemical or physical instability when it is mixed with other compounds.</p><p>Chemically incompatible with dexamethasone sodium phosphate, Heparin sodium, methicillin sodium, phenobarbitone sodium, sodium bicarbonate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 Months 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C. Keep container in the outer carton.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>500 mg: Clear Type I glass vial with rubber stopper in packs of 1 vial</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For single use. Discard any unused contents.</p><p><strong>Reconstitute Details:&nbsp; </strong></p><p><strong>Primary Diluent</strong> &ndash; Sterile water for Injection</p><p><strong>Secondary Diluent -</strong> 5% Dextrose and 0.9% Sodium Chloride Injection&nbsp;</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5% Dextrose and Lactated Ringer&#39;s Injection&nbsp;</p><p>&nbsp;</p><p><strong>Preparation and Stability: </strong></p><p>At the time of use reconstitute the vials of Vancomycin Hydrochloride for Injection USP with Sterile Water for Injection to a concentration of 50mg /mL of Vancomycin / mL.</p><p>&nbsp;</p><p>For 500mg Vial : 10mL of Diluent ( Sterile Water For Injection) to be used</p><p>For 1000mg Vial : 20mL of Diluent ( Sterile Water For Injection ) to be used</p><p>&nbsp;</p><p>After dilution store below 30&deg;C not more than 24 hours. Or in refrigerator 2 - 8 &deg;C for not more than 36 hours.</p><p>&nbsp;</p><p>Reconstituted solutions of Vancomycin (500mg/10mL) must be further diluted with at least 100mL of a suitable infusion solution.</p><p>Reconstituted solutions of Vancomycin (1000mg/20mL) must be further diluted with at least 200mL of a suitable infusion solution.</p><p>&nbsp;</p><p>The desired dose, diluted in this manner, should be administered by intermittent IV Infusion over a period of at least 60 minutes.</p><p>&nbsp;</p><p>Parenteral drug products should be visually inspected for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saudi Hetero Lab  
Aljameah Street, Malaz quarter, Riyadh 11441 
Saudi Arabia 
Tel: +966 11 477 2215
Manufacture: 
Aspiro Pharma Limited 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                21/11/2020 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>